ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Show more...
首席执行官
Mr. David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA
员工
35
国家
CA
上市
0 Comments
分享你的想法
FAQ
Essa Pharma 今天的股价是多少?▼
EPIX 当前价格为 C$0.2 CAD,在过去 24 小时内下跌了 -1.85%。在图表上更密切关注 Essa Pharma 股票的表现。